IntraBio

Executive Summary

IntraBio is a US-based private biopharmaceutical company focused on developing novel small molecule therapies for rare neurodegenerative and lysosomal storage diseases. Founded in 2015 and headquartered in Oxford, the company's late-stage pipeline centers on modified amino acids, with its lead candidate, IB1001, targeting Niemann-Pick disease type C (NPC), a rare and fatal genetic disorder. IB1001 has received Orphan Drug Designation from the FDA and EMA and is currently in Phase 3 clinical trials. The company's approach leverages intracellular calcium modulation to address the underlying pathology of NPC. IntraBio's differentiated platform could also be applicable to other neurological conditions, such as Alzheimer's and Parkinson's diseases, though these are at earlier stages. Given the high unmet need in NPC and positive early clinical data, IntraBio represents a compelling opportunity in the rare disease space, though execution risk remains given its private status and early-stage pipeline breadth.

Upcoming Catalysts (preview)

• Q4 2025Phase 3 top-line data for IB1001 in Niemann-Pick disease type C65% success
• Q2 2026Potential FDA filing for IB1001 (if Phase 3 successful)50% success
• Q1 2026Initiation of Phase 2 trial for IB1001 in Alzheimer's disease40% success